Literature DB >> 6831999

Tauroursodeoxycholic acid is less damaging than taurochenodeoxycholic acid to the gastric and esophageal mucosa.

K D Lillemoe, G W Kidder, J W Harmon, T R Gadacz, L F Johnson, R M Bunte, A F Hofmann.   

Abstract

Bile acids are capable of disrupting the gastric and esophageal mucosal barriers and are known to differ in their ability to injure these mucosae. Two bile acids, chenodeoxycholic and its 7-B epimer, ursodeoxycholic, that are being used to dissolve gallbladder stones were evaluated for their damaging effects on experimental preparations of the esophageal (rabbit) and gastric (dog) mucosa. Damage was assessed by measuring indices of mucosal barrier function, including net acid flux, potential difference, and tissue resistance, before and after exposure to the taurine conjugates of these bile acids. In both the esophageal and gastric mucosa, tauroursodeoxycholic acid caused significantly less disruption of barrier function than taurochenodeoxycholic acid. These results demonstrate that minor differences in conjugated bile acid structure can cause major changes in the effects of bile acids on the upper gastrointestinal mucosa and that ursodeoxycholic acid may be the preferred bile acid for oral ingestion to dissolve gallbladder stones.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831999     DOI: 10.1007/bf01324955

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  Different mechanisms of hydrogen ion removal in stomach and duodenum.

Authors:  J W Harmon; M Woods; N J Gurll
Journal:  Am J Physiol       Date:  1978-12

2.  Duodeno-gastric reflux and acid secretion in patients with symptomatic hiatal hermia.

Authors:  D W Stol; G M Murphy; J L Collis
Journal:  Scand J Gastroenterol       Date:  1974       Impact factor: 2.423

3.  Cholesterol gallstone dissolution in bile: dissolution kinetics of crystalline (anhydrate and monohydrate) cholesterol with chenodeoxycholate, ursodeoxycholate, and their glycine and taurine conjugates.

Authors:  H Igimi; M C Carey
Journal:  J Lipid Res       Date:  1981-02       Impact factor: 5.922

4.  Acute gastric mucosal ulcerogenesis is dependent on the concentration of bile salt.

Authors:  W P Ritchie; E W Shearburn
Journal:  Surgery       Date:  1976-07       Impact factor: 3.982

5.  Mechanism by which bile salt disrupts the gastric mucosal barrier in the dog.

Authors:  W C Duane; D M Wiegand
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

6.  Effects of bile salts on amphibian gastric mucosa.

Authors:  W Silen; J G Forte
Journal:  Am J Physiol       Date:  1975-02

7.  Role of the components of the gastroduodenal contents in experimental acid esophagitis.

Authors:  K D Lillemoe; L F Johnson; J W Harmon
Journal:  Surgery       Date:  1982-08       Impact factor: 3.982

8.  Effects of chenodeoxy- and ursodeoxycholic acid on absorption, secretion and permeability in rat colon and small intestine.

Authors:  W F Caspary; K Meyne
Journal:  Digestion       Date:  1980       Impact factor: 3.216

9.  Differing ulcerogenic potential of dihydroxy and trihydroxy bile acids in canine gastric mucosa.

Authors:  W P Ritchie; T S Felger
Journal:  Surgery       Date:  1981-03       Impact factor: 3.982

10.  Ursodeoxycholic acid treatment of gallstones. Dose-response study and possible mechanism of action.

Authors:  P N Maton; G M Murphy; R H Dowling
Journal:  Lancet       Date:  1977 Dec 24-31       Impact factor: 79.321

View more
  3 in total

1.  Further studies on the inhibition of pepsin by bile salts.

Authors:  T Eto; R K Tompkins
Journal:  Ann Surg       Date:  1986-01       Impact factor: 12.969

2.  Gastric mucosal toxicity of duodenal juice constituents in the rat. Acute studies using ex vivo rat gastric chamber model.

Authors:  D Armstrong; E R Rytina; G M Murphy; R H Dowling
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

3.  Altered migrating myoelectrical complex in an animal model of cholesterol gallstone disease: the effect of erythromycin.

Authors:  Q W Xu; R B Scott; D T Tan; E A Shaffer
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.